ヘリコバクターピロリ菌ワクチンの世界市場機会分析

VacZine Analyticsが発行した調査報告書(VACZ51201)
◆英語タイトル:MarketVIEW: Helicobacter pylori vaccines - Vaccine opportunity assessment
◆商品コード:VACZ51201
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2015年12月
◆ページ数:50以上
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆販売価格オプション(消費税別)
Executive Presentation (PDF)GBP3,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
PDF+ExcelGBP6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、ヘリコバクターピロリ菌ワクチンの世界市場機会について調査・分析し、ヘリコバクターピロリ菌感染症の概要、疫学トレンド、リスク要因、ヘリコバクターピロリ菌感染症の診断、治療戦略、研究開発動向、ワクチン接種へのアプローチ、ワクチン開発における重要要素、ターゲット製品プロファイル、商用化/市場予測モデリング・シナリオ、価格分析、ヘリコバクターピロリ菌ワクチンの市場規模予測結果(金額及びボリューム)、予防ワクチン市場、治療ワクチン市場予測などの情報をお届けいたします。
【レポートの概要】

Helicobacter pylori is one of world’s most common infections with approximately half to two thirds of the world’s population harbouring the bacterium. H.pylori, which colonizes the human stomach mucosa, can cause active, chronic persistent and atrophic gastritis in adults and children. The bacterium causes more than 90% of duodenal ulcers and up to 80% of gastric cancers. Gastric cancer is the third most common cause of cancer-related deaths in the world, killing approximately 723,000 people in 2012.

H.pylori infection can be eradicated by use of antibiotics and proton-pump inhibitor (PPI) therapy. However, the therapy can be demanding in terms of patient compliance and its effectiveness is impacted by antibiotic resistance. Around 20% of patients fail first line therapy and re-infection is common. Importantly, individuals are only treated on presentation with symptoms because a population wide eradication program is unfeasible. Many investigators have attempted to develop both H.pylori therapeutic and prophylatic vaccines with little clinical success. However, an oral urease vaccine was approved in China in 2009 after showing efficacy in Phase III studies in children

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value H.pylori prophylatic and therapeutic vaccines across relevant markets to 2035. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the amount of countries targeted by a potential prophylatic vaccine. The therapeutic vaccine model focuses on new and ever (recurrent cases) of peptic ulcer disease.

【レポートの目次】

※レポート紹介PDF⇒http://www.vaczine-analytics.com/VAMV065_TOC_151130.pdf

****This product is composed of two forecast models and a summary presentation

Title page
Author’s note
Contents
Executive summary
H.pylori prophylatic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori prophylatic vaccine: volumes per scenario to 2035 (000s)
H.pylori prophylatic vaccine: revenues – China and Japan ($ 000s)
H.pylori therapeutic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori therapeutic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori therapeutic vaccine: revenues to 2035 ($ 000s) new cases
H.pylori therapeutic vaccine: revenues to 2035 ($ 000s) ever cases
H.pylori: Epidemiology and general disease background
The pathogen
H.pylori: epidemiologic burden
H.pylori: epidemiologic burden (Western countries)
United States: seroprevalence of H.pylori
H.pylori: global prevalence map
H.pylori – trends in epidemiology
What is the outcome of H.pylori infection?
What is the outcome of H.pylori infection?
Natural history of H.pylori infection
H.pylori – molecular pathogenesis
H.pylori – mechanism of tumorigenesis
Diagnosis of H.pylori infection
H.pylori and gastric cancer: general background
Gastric Cancer Estimated Incidence, Worldwide in 2012: Men
Gastric cancer: incidence rates per top 20 countries, 2012
Gastric cancer: focus countries – China and Japan
Trends in incidence of stomach cancer in selected countries: age-standardised rate per 100,000, men
H.pylori and non cardia gastric cancer and CagA strains
Global distribution of cag pathogenicity island
Major outcome: peptic ulcer disease
Peptic ulcer disease and H.pylori infection
Diagnosis of H.pylori infection
Indications for H.pylori treatment
Treatment of H.pylori infection
First-Line Regimens for H.pylori eradication
H.pylori treatment: understanding patient flow (PUD)
H.pylori and antibiotic resistance, other factors
H.pylori and antibiotic resistance (developing world)
Economic burden of Gastrointestinal diseases
Peptic ulcer disease: pharmaceuticals market value (2017)
H.pylori eradication therapy: global market value 2005
H.pylori – other disease outcomes
H.pylori vaccine development
History of R&D approaches and current status
The medical need for a H.pylori vaccine
Notable challenges to H.pylori vaccine development
History of H.pylori vaccine development (preclinical)
Potential H.pylori vaccine antigens (preclinical studies)
H.pylori vaccines: past human studies
Clinical trials for vaccine efficacy against H.pylori: summary
H.pylori vaccine: Chinese study – Chong Qing Kang Wei (CQKW)
H.pylori vaccine (CQKW): – Phase III data
CQKW vaccine – a major advance?
CQKW vaccine: potential obstacles for Western use
CQKW vaccine – current status
H.pylori vaccines – other R&D approaches (ImevaX GmbH)
H.pylori vaccines – other R&D approaches (AMRIC – Canada)
H.pylori vaccines – other R&D approaches (EpiVax)
The cost effectiveness of a H.pylori vaccine
H.pylori vaccines: modelling commercial potential
Broad target populations for a H.pylori vaccine (PX & TX)
Drivers and resistors to prophylatic vaccine (PX)
Drivers and resistors to therapeutic vaccine (TX)
H.pylori vaccines: Target Product Profiles (TPPs)
Modelling methodology: prophylatic vaccine (PX)
PX vaccine: hypothetical launch sequence
PX vaccine: hypothetical launch sequence: LO scenario
PX vaccine: hypothetical launch sequence: Base scenario
PX vaccine: hypothetical launch sequence: HI scenario
PX vaccine: predicted vaccine coverage (< 1yrs)
PX vaccine: predicted vaccine coverage (preadolescence)
PX vaccine: pricing estimates – guiding assumptions
PX vaccine: pricing estimates – summary
H.pylori therapeutic vaccine (PX): vaccine positioning
Modelling methodology: therapeutic vaccine (TX)
Peptic ulcer disease patient segmentation
Modelling new PUD cases (TX vaccine)
Modelling recurrent ever cases (TX vaccine)
TX vaccine: other modelling assumptions
TX vaccine: potential upsides
Bibliography



【レポートのキーワード】

ヘリコバクターピロリ菌、ピロリ菌感染、ピロリ菌予防ワクチン、ピロリ菌治療ワクチン、ワクチン、治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ヘリコバクターピロリ菌ワクチンの世界市場機会分析(MarketVIEW: Helicobacter pylori vaccines - Vaccine opportunity assessment)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆